Case report
peer-reviewed
Published: November 11, 2022 (see history)
DOI: 10.7759/cureus.31385
Cite this nonfiction as: Prasad S, Colon Figueroa P, Stead T S, et al. (November 11, 2022) Intraparenchymal Hematoma With Significant Mass Effect Treated With Factor Eight Inhibitor Bypass Activity. Cureus 14(11): e31385. doi:10.7759/cureus.31385
Abstract
The authors present the lawsuit of an 80-year-old pistillate with myelodysplastic syndrome treated with chemotherapy and apixaban, a nonstop oral anticoagulant who suffered an intracranial hemorrhage. She presented to the exigency section with altered intelligence presumption and was recovered to person a ample intraparenchymal hematoma with a important wide effect. Our diligent was fixed FEIBA (Factor Eight Inhibitor Bypass Activity) to reverse the hemorrhage. Anticoagulant-related bleeding reversal strategies are discussed.
Introduction
Intracerebral hemorrhage (ICH), of which intraparenchymal hematomas are a subtype, makes up little than 20% of each changeable cases but is associated with early-term mortality of 30% to 40% [1]. The mortality remains precocious contempt decreasing incidence [2]. Amongst survivors, little than 50% are capable to instrumentality to their erstwhile level of activity.
Risk factors for ICH see anterior ICH, hypertension, hyperlipidemia, diabetes, metabolic syndrome, myeloid angiopathy, and galore medications. Drugs that summation the hazard of ICH see vasoconstrictive agents specified arsenic triptans and selective serotonin re-uptake inhibitors, decongestants, stimulants, phentermine, and sympathomimetic drugs. Estrogen-containing oral contraceptives tin effect successful hemorrhage attributable to cerebral venous sinus thrombosis. Furthermore, drugs of maltreatment specified arsenic tobacco, marijuana, cocaine, alcohol, and amphetamines besides summation the hazard of ICH [3].
The accepted presumption of ICH is simply a abrupt onset of focal neurological deficits, which advancement rapidly implicit the people of minutes to hours [4]. The deficits are often accompanied by nausea, headache, decreased consciousness, and elevated humor pressure.
The main goals successful the emergent absorption of ICH are to forestall further bleeding, and measure whether surgical involution is of benefit. Towards this end, the absorption is connected humor unit power and agents directed astatine reversing immoderate underlying coagulopathy. Our diligent was connected a nonstop oral anticoagulant (DOAC) for her myelodysplastic syndrome and was fixed FEIBA (Factor Eight Inhibitor Bypass Activity) to reverse the hemorrhage.
Case Presentation
An 80-year-old pistillate presented to the exigency section (ED) with a deteriorating intelligence status. The patient’s lad stated that she had afloat cognitive relation the erstwhile night. She started feeling sick the greeting of the ED presentation and vomited a fewer times. A fewer hours later, she was incapable to portion h2o with a straw, and could lone reply questions with “gibberish.” Her symptoms evolved until she could nary longer unfastened her eyes oregon talk. Her past aesculapian past was important for a myelodysplastic syndrome which was being treated with chemotherapy and apixaban, a DOAC. She had taken her medicine wrong the erstwhile 12 hours. Her lad stated she did not fume oregon usage immoderate recreational drugs oregon alcohol.
Her captious signs included a somesthesia of 98.5°F, humor unit of 138/81 mmHg, a pulse of 100 beats per minute, a respiration complaint of 16 breaths per minute, and an oxygen saturation of 96% connected country air. Physical introspection showed aggregate areas of ecchymosis of antithetic ages, including periorbital ecchymosis, but nary oculus injury. She besides had scattered petechiae. The diligent lone opened her eyes to noxious stimuli and moaned a fewer times. She was, however, able to support her airway. Her Glasgow coma people was a 9 (E2V2M5). Her cardiopulmonary and abdominal exams were unremarkable. Laboratory investigation was important for terrible thrombocytopenia, anemia, hyperglycemia, mild hypokalemia, and hyponatremia (Table 1).
Patient result | Reference scope (hospital standard) | |
Blood Gas | ||
POC ABG pH | 7.42 | (7.35 - 7.45) |
POC ABG pCO2 | 25.3 L | (35 - 45 mmHg) |
POC ABG pO2 | 81 | (80 - 105 mmHg) |
POC ABG HCO3 | 16.3 L | (22-26 mmol/L) |
ABG Total CO2 | 17 L | (23 - 27 mmol/L) |
ABG O2 Saturation | 96% | (95-98%) |
POC ABG Base Excess | -7 L | (-2-3 mmol/L) |
Chemistry | ||
Sodium | 134 L | 136 - 145 mmol/L |
Potassium | 3.6 L | 3.7 - 5.1 mmol/l |
Chloride | 97 L | 98 - 107 mmol/L |
Carbon Dioxide | 18 L | 21 - 32 mmol/l |
Anion Gap | 22.6 | 7 - 18 mg/dl |
Blood Urea Nitrogen | 25 H | 0.55 - 1.3 mg/dl |
Creatinine | 1.21 | 0.6 - 1.3 mg/dL |
Glucose | 267 H | 74 - 106 mg/dl |
Calcium | 9.2 | 8.4 - 10.1 mg/dl |
Total Bilirubin | 1.4 | 0.2 - 1.5 mg/dl |
Aspartate Transaminase | 11 | 10 - 37 unit/L |
Alanine Aminotransferase | 8 L | 12 - 78 unit/L |
Total Alkaline Phosphatase | 61 | 45 - 117 unit/L |
Creatine Kinase | 40 | 21 - 215 unit/L |
Total Protein | 7 | 6.4 - 8.2 g/dL |
Albumin | 3.1 L | 3.4 - 5.0 g/dl |
Coagulation Studies | ||
Prothrombin Time | 13.3 H | 9.0 - 12.7 seconds |
International Normalized Ratio | 1.3 H | 0.85 - 1.17 |
Hematology | ||
White Blood Cell Count | 2.13 L | 4.0 - 12.0 K/mm3 |
Hemoglobin | 6.3 C | 12.0 - 16.0 gm/dL |
Hematocrit | 19.0 C | 37.0 - 47.0 % |
Platelet Count | 1 C | 130 - 400 K/mm3 |
Immature Granulocytes % | 1 H | 0 - 0.22 % |
Neutrophils % | 52.1 | 38.0 - 74.0 % |
Lymphocytes % | 40.8 | 20 - 45 % |
Monocytes % | 6.6 | 3 - 10 % |
Eosinophils % | 0 | 0 - 4 % |
Basophils % | 0 | 0 - 2.0 % |
Noncontrast encephalon CT demonstrated a ample near frontal intraparenchymal hematoma with important wide effect, resulting from a midline displacement anteriorly near to close of astir 11 mm. Also contiguous was extra-axial hemorrhage successful the parafalcine portion arsenic good arsenic anterior to the bilateral frontal lobes and successful the basal cisterns. Additionally, determination was an intraventricular hold of hemorrhage, comparative effacement of the near lateral ventricle, and hemorrhage successful the occipital horns of the lateral ventricles bilaterally. The near parietal parenchyma demonstrated a rounded absorption astir 1.4 cm successful diameter, and a tiny measurement subarachnoid hemorrhage is seen successful adjacent proximity astatine the near parietal cortex (Figure 1).
Her ICH people was a 4, with 1 constituent each for property 80, GCS betwixt 5-12, ICH measurement > 30 cubic centimeters, and the beingness of intraventricular blood. The diligent was fixed FEIBA for reversal of anticoagulation and a platelet transfusion. An ICH people of 4 is mostly associated with a 97% mortality. Given her mediocre prognosis, the household opted for hospice care.
Discussion
Coagulopathy-associated ICH is an further hazard origin for mortality and mediocre functional result with hematoma enlargement which whitethorn hap wrong 1 hr successful up to 25% of patients and wrong 4 hours successful 88% of patients. Anticoagulant-related ICH is simply a aesculapian exigency that requires emergent reversal [5]. Oral anticoagulation usage is expanding owed to the aging colonisation and the associated summation successful patients with cardiovascular comorbidities. There are respective reversal agents available, with availability varying by the institution. Current anticoagulation options include vitamin K antagonists (VKAs) specified arsenic Warfarin and DOACs. DOACs are divided into 2 classes; nonstop thrombin inhibitors and origin Xa inhibitors. Treatment should beryllium initiated based connected neuroimaging and objective accusation specified arsenic benignant and clip of anticoagulant dosing alternatively than waiting for laboratory results [3].
Warfarin interferes with the accumulation of vitamin K-dependent clotting factors II, VII, IX, and X by depleting vitamin K reserve [5]. Warfarin-related coagulopathy is usually treated with Prothrombin Complex Concentrate (PCC) which corrects coagulopathy by replacing each 4 vitamin K-dependent factors. It tin beryllium administered successful a accelerated tiny measurement for which it is considered the preferred treatment. Fresh Frozen Plasma (FFP) is derived from full humor products and works by replacing plasma proteins with replete clotting factors. FFP is ineffective successful the acute setting because reversal of INR (international normalized ratio) with FFP whitethorn instrumentality up to 24 hours. Additionally, FFP requires precocious volumes and tin worsen fluid equilibrium which whitethorn pb to pulmonary edema successful patients with bosom failure.
Heparin-induced coagulopathy is treated with protamine sulfate. Dosage whitethorn alteration depending connected the duration of the past dose and the route; subcutaneous oregon intravenous way [6]. DOACs person been shown to beryllium safer than warfarin successful presumption of risk of changeable oregon systemic embolism, intracranial bleeding, and all-cause decease compared with warfarin [7]. Given their safety, efficacy, and easiness of use, their usage has been increasing.
Andexanet alfa is a reversal cause for origin Xa inhibitors and is presently the lone FDA-approved cause for apixaban and rivaroxaban. The single-arm ANNEXA-4 survey reported 82% of patients had fantabulous oregon bully hemostatic efficacy astatine 12 hours, aft the medication of andexanet alfa [8]. Given its outgo and constricted availability, PCC is inactive commonly used. There is insufficient grounds astir risks and benefits to powerfully favour either 4-factor PCC oregon andexanet implicit the other; these reversal agents person not been compared with each different straight successful a randomized trial. Data comparing outcomes successful patients fixed either andexanet alfa oregon PCC are constricted by baseline imbalances betwixt the groups attributable to enactment bias [3].
Factor VIII inhibitor bypassing enactment (FEIBA), an activated prothrombin macromolecule analyzable concentrate, is besides utilized arsenic an off-label origin Xa inhibitor reversal agent. It controls bleeding by induction and facilitation of thrombin procreation [9]. A fewer studies study bully hemostasis with FEIBA successful DOAC-associated bleeding. A lawsuit bid of 104 patients that utilized FEIBA specifically for bleeding secondary to apixaban oregon rivaroxaban obtained hemostasis successful 89% of patients [10].
A survey of 64 consecutive patients connected a DOAC recovered some low-dose FEIBA (<20 units/kg) and mean doses (20-30 units/kg) to beryllium an effectual absorption strategy for obtaining hemostasis successful DOAC-related ICH [11]. Despite a fistful of studies reporting that FEIBA is simply a harmless and effectual cause for the reversal of apixaban and rivaroxaban, it is inactive considered off-label for DOAC-associated bleeding astatine the clip of this writing.
Conclusions
There are aggregate ways to negociate coagulopathy-associated ICH, specified arsenic PCC, andexanet alfa, and FEIBA. Overall, determination has been important advancement successful the options for the absorption of ICH successful patients connected oral anticoagulation. Failure to code coagulopathy whitethorn effect successful the hold of neurosurgical intervention, an summation successful the size of the hematoma, and an accrued hazard of mortality.
References
- van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ: Incidence, lawsuit fatality, and functional result of intracerebral haemorrhage implicit time, according to age, sex, and taste origin: a systematic reappraisal and meta-analysis. Lancet Neurol. 2010, 9:167-76. 10.1016/S1474-4422(09)70340-0
- Zahuranec DB, Lisabeth LD, Sánchez BN, et al.: Intracerebral hemorrhage mortality is not changing contempt declining incidence. Neurology. 2014, 82:2180-6. 10.1212/WNL.0000000000000519
- Greenberg SM, Ziai WC, Cordonnier C, et al.: 2022 line for the absorption of patients with spontaneous intracerebral hemorrhage: a line from the American Heart Association/American Stroke Association. Stroke. 2022, 53:e282-361. 10.1161/STR.0000000000000407
- An SJ, Kim TJ, Yoon BW: Epidemiology, hazard factors, and objective features of intracerebral hemorrhage: an update. J Stroke. 2017, 19:3-10. 10.5853/jos.2016.00864
- Sweidan AJ, Singh NK, Conovaloff JL, Bower M, Groysman LI, Shafie M, Yu W: Coagulopathy reversal successful intracerebral haemorrhage. Stroke Vasc Neurol. 2020, 5:29-33. 10.1136/svn-2019-000274
- Dhakal P, Rayamajhi S, Verma V, Gundabolu K, Bhatt VR: Reversal of anticoagulation and absorption of bleeding successful patients connected anticoagulants. Clin Appl Thromb Hemost. 2017, 23:410-5. 10.1177/1076029616675970
- Carnicelli AP, Hong H, Connolly SJ, et al.: Direct oral anticoagulants versus warfarin successful patients with atrial fibrillation: patient-level web meta-analyses of randomized objective trials with enactment investigating by property and sex. Circulation. 2022, 145:242-55. 10.1161/CIRCULATIONAHA.121.056355
- Connolly SJ, Crowther M, Eikelboom JW, et al.: Full survey study of andexanet alfa for bleeding associated with origin Xa inhibitors. N Engl J Med. 2019, 380:1326-35. 10.1056/NEJMoa1814051
- Turecek PL, Váradi K, Gritsch H, Schwarz HP: FEIBA: mode of action. Haemophilia. 2004, 10 Suppl 2:3-9. 10.1111/j.1365-2516.2004.00934.x
- Hunt AR, Coffeen SN, Shiltz DL, Ice C, Parker J: Factor VIII inhibitor bypassing enactment (FEIBA) reversal for apixaban and rivaroxaban successful patients with acute intracranial and nonintracranial hemorrhage. Ann Pharmacother. 2021, 55:1455-66. 10.1177/10600280211004583
- Dager WE, Roberts AJ, Nishijima DK: Effect of debased and mean dose FEIBA to reverse large bleeding successful patients connected nonstop oral anticoagulants. Thromb Res. 2019, 173:71-6. 10.1016/j.thromres.2018.11.009
Case report
peer-reviewed
Intraparenchymal Hematoma With Significant Mass Effect Treated With Factor Eight Inhibitor Bypass Activity
Author Information
Sathwika Prasad
Emergency Medicine, University of Central Florida College of Medicine, Orlando, USA
Thor S. Stead
Medicine, The Warren Alpert Medical School of Brown University, Providence, USA
Rohan K. Mangal
Medicine, University of Miami Miller School of Medicine, Miami, USA
Latha Ganti Corresponding Author
Emergency Medicine, HCA Florida Ocala Hospital, Ocala, USA
Emergency Medicine, Envision Physician Services, Plantation, USA
Emergency Medicine, University of Central Florida College of Medicine, Orlando, USA
Ethics Statement and Conflict of Interest Disclosures
Human subjects: Consent was obtained oregon waived by each participants successful this study. HCA Centralized Algorithms for Research Rules connected IRB Exemptions (CARRIE)/ IRB manager issued support #2022-901. HCA Centralized Algorithms for Research Rules connected IRB Exemptions (CARRIE)/ IRB manager issued survey exemption #2022-901. Conflicts of interest: In compliance with the ICMJE azygous disclosure form, each authors state the following: Payment/services info: All authors person declared that nary fiscal enactment was received from immoderate enactment for the submitted work. Financial relationships: All authors person declared that they person nary fiscal relationships astatine contiguous oregon wrong the erstwhile 3 years with immoderate organizations that mightiness person an involvement successful the submitted work. Other relationships: All authors person declared that determination are nary different relationships oregon activities that could look to person influenced the submitted work.
Acknowledgements
This probe was supported (in full oregon successful part) by HCA Healthcare and/or an HCA Healthcare-affiliated entity. The views expressed successful this work correspond those of the author(s) and bash not needfully correspond the authoritative views of HCA Healthcare oregon immoderate of its affiliated entities.
Article Information
DOI
10.7759/cureus.31385
Cite this nonfiction as:
Prasad S, Colon Figueroa P, Stead T S, et al. (November 11, 2022) Intraparenchymal Hematoma With Significant Mass Effect Treated With Factor Eight Inhibitor Bypass Activity. Cureus 14(11): e31385. doi:10.7759/cureus.31385
Publication history
Peer reappraisal began: October 14, 2022
Peer reappraisal concluded: November 05, 2022
Published: November 11, 2022
Copyright
© Copyright 2022
Prasad et al. This is an unfastened entree nonfiction distributed nether the presumption of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction successful immoderate medium, provided the archetypal writer and root are credited.
License
This is an unfastened entree nonfiction distributed nether the presumption of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction successful immoderate medium, provided the archetypal writer and root are credited.
Case report
peer-reviewed
Intraparenchymal Hematoma With Significant Mass Effect Treated With Factor Eight Inhibitor Bypass Activity
Figures etc.
Patient result | Reference scope (hospital standard) | |
Blood Gas | ||
POC ABG pH | 7.42 | (7.35 - 7.45) |
POC ABG pCO2 | 25.3 L | (35 - 45 mmHg) |
POC ABG pO2 | 81 | (80 - 105 mmHg) |
POC ABG HCO3 | 16.3 L | (22-26 mmol/L) |
ABG Total CO2 | 17 L | (23 - 27 mmol/L) |
ABG O2 Saturation | 96% | (95-98%) |
POC ABG Base Excess | -7 L | (-2-3 mmol/L) |
Chemistry | ||
Sodium | 134 L | 136 - 145 mmol/L |
Potassium | 3.6 L | 3.7 - 5.1 mmol/l |
Chloride | 97 L | 98 - 107 mmol/L |
Carbon Dioxide | 18 L | 21 - 32 mmol/l |
Anion Gap | 22.6 | 7 - 18 mg/dl |
Blood Urea Nitrogen | 25 H | 0.55 - 1.3 mg/dl |
Creatinine | 1.21 | 0.6 - 1.3 mg/dL |
Glucose | 267 H | 74 - 106 mg/dl |
Calcium | 9.2 | 8.4 - 10.1 mg/dl |
Total Bilirubin | 1.4 | 0.2 - 1.5 mg/dl |
Aspartate Transaminase | 11 | 10 - 37 unit/L |
Alanine Aminotransferase | 8 L | 12 - 78 unit/L |
Total Alkaline Phosphatase | 61 | 45 - 117 unit/L |
Creatine Kinase | 40 | 21 - 215 unit/L |
Total Protein | 7 | 6.4 - 8.2 g/dL |
Albumin | 3.1 L | 3.4 - 5.0 g/dl |
Coagulation Studies | ||
Prothrombin Time | 13.3 H | 9.0 - 12.7 seconds |
International Normalized Ratio | 1.3 H | 0.85 - 1.17 |
Hematology | ||
White Blood Cell Count | 2.13 L | 4.0 - 12.0 K/mm3 |
Hemoglobin | 6.3 C | 12.0 - 16.0 gm/dL |
Hematocrit | 19.0 C | 37.0 - 47.0 % |
Platelet Count | 1 C | 130 - 400 K/mm3 |
Immature Granulocytes % | 1 H | 0 - 0.22 % |
Neutrophils % | 52.1 | 38.0 - 74.0 % |
Lymphocytes % | 40.8 | 20 - 45 % |
Monocytes % | 6.6 | 3 - 10 % |
Eosinophils % | 0 | 0 - 4 % |
Basophils % | 0 | 0 - 2.0 % |